Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk score-guided switch from standard half-life factor VIII prophylaxis to Jivi in hemophilia A
2021-006191-16Phase 4
- Sponsor
- Bayer
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Primary endpoint: Occurrence of favorable outcome on the score selected dosing regimen.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2021-006191-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006191-16.